Drugs that contain Plazomicin Sulfate

1. List of Zemdri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9688711 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US8383596 CIPLA USA Antibacterial aminoglycoside analogs
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9266919 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US8822424 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

Do you want to check out ZEMDRI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 25, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 25, 2028

NCE-1 date: 2027-06-26

Market Authorisation Date: 25 June, 2018

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ZEMDRI family patents

11

United States

2

China

2

Japan

2

European Union

1

Spain

1

Denmark

1

Poland

1

Brazil

1

Canada

EA

1

EA

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic